<SEC-DOCUMENT>0001213900-25-035092.txt : 20250424
<SEC-HEADER>0001213900-25-035092.hdr.sgml : 20250424
<ACCEPTANCE-DATETIME>20250424163002
ACCESSION NUMBER:		0001213900-25-035092
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250424
DATE AS OF CHANGE:		20250424

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SONIM TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001178697
		STANDARD INDUSTRIAL CLASSIFICATION:	TELEPHONE & TELEGRAPH APPARATUS [3661]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				943336783
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91008
		FILM NUMBER:		25867767

	BUSINESS ADDRESS:	
		STREET 1:		4445 EASTGATE MALL
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		650-378-8100

	MAIL ADDRESS:	
		STREET 1:		4445 EASTGATE MALL
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AJP Holding Company, LLC
		CENTRAL INDEX KEY:			0001932469
		ORGANIZATION NAME:           	
		EIN:				881673601

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		2140 S. DUPONT HIGHWAY
		CITY:			CAMDEN
		STATE:			DE
		ZIP:			19934
		BUSINESS PHONE:		408-507-9307

	MAIL ADDRESS:	
		STREET 1:		2140 S. DUPONT HIGHWAY
		CITY:			CAMDEN
		STATE:			DE
		ZIP:			19934
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: AJP Holding Company, LLC -->
          <cik>0001932469</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>8</amendmentNo>
      <securitiesClassTitle>common stock, $0.001 par value</securitiesClassTitle>
      <dateOfEvent>04/24/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001178697</issuerCIK>
        <issuerCUSIP>83548F309</issuerCUSIP>
        <issuerName>SONIM TECHNOLOGIES INC</issuerName>
        <address>
          <com:street1>4445 Eastgate Mall</com:street1>
          <com:street2>Suite 200</com:street2>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>9212</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Arthur Marcus, Esq.</personName>
          <personPhoneNum>212-930-9700</personPhoneNum>
          <personAddress>
            <com:street1>Sichenzia Ross Ference Carmel</com:street1>
            <com:street2>1185 Avenue of the Americas, 31st floor</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10036</com:zipCode>
          </personAddress>
        </notificationInfo>
        <notificationInfo>
          <personName>Richard F. Langan, Jr., Esq.</personName>
          <personPhoneNum>(212) 940-3000</personPhoneNum>
          <personAddress>
            <com:street1>Nixon Peabody LLP</com:street1>
            <com:street2>55 West 46th Street</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10036</com:zipCode>
          </personAddress>
        </notificationInfo>
        <notificationInfo>
          <personName>Conrad Adkins, Esq.</personName>
          <personPhoneNum>(212) 940-3000</personPhoneNum>
          <personAddress>
            <com:street1>Nixon Peabody LLP</com:street1>
            <com:street2>55 West 46th Street</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10036</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001932469</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>AJP Holding Company, LLC</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1946345.00</sharedDispositivePower>
        <aggregateAmountOwned>1946345.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>30.7</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>(1) Beneficial ownership of the shares of common stock owned by AJP Holding Company, LLC are also attributable to (i) Jeffrey Wang, the sole manager of AJP Holding Company, LLC; (ii) Orbic North America, LLC; (iii) Ashima Narula, the sole member and manager of Orbic North America, LLC.; and (iv) Parveen Narula, the Chief Executive Officer of Orbic North America, LLC. and, thus, are reported by more than one Reporting Person pursuant to Rule 13d-3 under the Act. (2) Percentage calculated based on 6,324,057 shares of common stock outstanding on March 24, 2025, as reported in the Form 10-K filed by the Issuer on March 31, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Jeffrey Wang</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1946345.00</sharedDispositivePower>
        <aggregateAmountOwned>1946345.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>30.7</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>(1) Beneficial ownership of the shares of common stock owned by AJP Holding Company, LLC are also attributable to: (i) Jeffrey Wang, the sole manager of AJP Holding Company, LLC; (ii) Orbic North America, LLC; (iii) Ashima Narula, the sole member and manager of Orbic North America, LLC.; and (iv) Parveen Narula, the Chief Executive Officer of Orbic North America, LLC., and, thus, are reported by more than one Reporting Person pursuant to Rule 13d-3 under the Act. (2) Percentage calculated based on 6,324,057 shares of common stock outstanding on March 24, 2025, as reported in the Form 10-K filed by the Issuer on March 31, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Orbic North America, LLC.</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>WC</fundType>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>NY</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1000.00</sharedDispositivePower>
        <aggregateAmountOwned>1947345.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>30.7</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>(1) Beneficial ownership of the shares of common stock owned by AJP Holding Company, LLC are also attributable to: (i) Jeffrey Wang, the sole manager of AJP Holding Company, LLC; (ii) Orbic North America, LLC; (iii) Ashima Narula, the sole member and manager of Orbic North America, LLC.; and (iv) Parveen Narula, the Chief Executive Officer of Orbic North America, LLC., and, thus, are reported by more than one Reporting Person pursuant to Rule 13d-3 under the Act. (2) Percentage calculated based on 6,324,057 shares of common stock outstanding on March 24, 2025, as reported in the Form 10-K filed by the Issuer on March 31, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Ashima Narula</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>WC</fundType>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1947345.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1000.00</sharedDispositivePower>
        <aggregateAmountOwned>1947345.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>30.7</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>(1) Beneficial ownership of the shares of common stock owned by AJP Holding Company, LLC are also attributable to: (i) Jeffrey Wang, the sole manager of AJP Holding Company, LLC; (ii) Orbic North America, LLC; (iii) Ashima Narula, the sole member and manager of Orbic North America, LLC.; and (iv) Parveen Narula, the Chief Executive Officer of Orbic North America, LLC., and, thus, are reported by more than one Reporting Person pursuant to Rule 13d-3 under the Act. (2) Percentage calculated based on 6,324,057 shares of common stock outstanding on March 24, 2025, as reported in the Form 10-K filed by the Issuer on March 31, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Parveen Narula</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>WC</fundType>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1947345.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1000.00</sharedDispositivePower>
        <aggregateAmountOwned>1947345.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>30.7</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>(1) Beneficial ownership of the shares of common stock owned by AJP Holding Company, LLC are also attributable to: (i) Jeffrey Wang, the sole manager of AJP Holding Company, LLC; (ii) Orbic North America, LLC; (iii) Ashima Narula, the sole member and manager of Orbic North America, LLC.; and (iv) Parveen Narula, the Chief Executive Officer of Orbic North America, LLC., and, thus, are reported by more than one Reporting Person pursuant to Rule 13d-3 under the Act. (2) Percentage calculated based on 6,324,057 shares of common stock outstanding on March 24, 2025, as reported in the Form 10-K filed by the Issuer on March 31, 2025.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>common stock, $0.001 par value</securityTitle>
        <issuerName>SONIM TECHNOLOGIES INC</issuerName>
        <issuerPrincipalAddress>
          <com:street1>4445 Eastgate Mall</com:street1>
          <com:street2>Suite 200</com:street2>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>9212</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>Introductory Statement: This Amendment No. 7 (this "Amendment "), being filed by AJP Holding Company, LLC ("AJP"), Jeffrey Wang, Orbic North America, LLC ("Orbic"), Ashima Narula and Parveen Narula, the ("Reporting Persons"), amends and supplements the (i) Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on July 19, 2022, (ii) the Amendment No. 1 to Schedule 13D filed with the SEC on October 25, 2022, (iii) the Amendment No. 2 to the Schedule 13D filed with the SEC on January 17, 2025, (iv) the Amendment No. 3 to the Schedule 13D filed with the SEC on March 18, 2025, (v) the Amendment No. 4 to the Schedule 13D filed with the SEC on March 24, 2025, (vi) the Amendment No. 5 to the Schedule 13D filed with the SEC on March 31, 2025, (vii) the Amendment No. 6 to the Schedule 13D filed with the SEC on April 10, 2025, and (viii) the Amendment No. 7 to the Schedule 13D filed with the SEC on April 16, 2025 (collectively, the "Schedule 13D"). This Schedule 13D relates to the shares of common stock (the "Common Stock") of Sonim Technologies Inc., a Delaware corporation (the "Issuer"). Except as specifically provided herein, this Amendment No. 8 does not modify any of the information previously reported in the Schedule 13D, as amended. Capitalized terms used herein shall have the meanings ascribed to them in the Schedule 13D.</commentText>
      </item1>
      <item4>
        <transactionPurpose>Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On April 24, 2025, AJP on behalf of itself as a record holder of shares of common stock of the Issuer and on behalf of Orbic, filed a Verified Complaint (the "Complaint") in the Delaware Court of Chancery against the Issuer and certain members of the Issuer's Board of Directors (the "Director Defendants") seeking relief to (i) permanently enjoin the Issuer and its Board of Directors from taking any actions to prevent AJP and Orbic from exercising their rights in accordance with the Issuer's corporate bylaws to nominate directors, and (ii) find that the Director Defendants breached their fiduciary duties, as more fully described in the Complaint.

The foregoing description of the Complaint does not purport to be complete and is qualified in its entirety by reference to the full text of the Complaint, which is attached hereto as Exhibit 99.2 and is incorporated herein by reference.</transactionPurpose>
      </item4>
      <item7>
        <filedExhibits>Exhibit 99.1 Joint Filing Agreement among the Reporting Persons dated March 18, 2025.

Exhibit 99.2 Form of Verified Complaint, filed with the Delaware Court of Chancery on April 24, 2025.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>AJP Holding Company, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Jeffrey Wang</signature>
          <title>Jeffrey Wang, Manager</title>
          <date>04/24/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Jeffrey Wang</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Jeffrey Wang</signature>
          <title>Jeffrey Wang, Individual</title>
          <date>04/24/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Orbic North America, LLC.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Parveen Narula</signature>
          <title>Parveen Narula, Chief Executive Officer</title>
          <date>04/24/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Ashima Narula</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Ashima Narula</signature>
          <title>Ashima Narula, Individual</title>
          <date>04/24/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Parveen Narula</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Parveen Narula</signature>
          <title>Parveen Narula, Individual</title>
          <date>04/24/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea023943601ex99-1_sonim.htm
<DESCRIPTION>JOINT FILING AGREEMENT AMONG THE REPORTING PERSONS DATED MARCH 18, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Joint Filing Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with Rule 13d-1(k) promulgated under
the Securities Exchange Act of 1934, as amended, each of the persons and entities named below agrees to the joint filing of this Schedule
13D Amendment with respect to the shares of common stock, par value $0.001, of SONIM Technologies Inc., a corporation incorporated under
the laws of Delaware, and further agrees that this Joint Filing Agreement be filed with the Securities and Exchange Commission as an exhibit
to such filing; provided no such person or entity shall be responsible for the completeness of any other person or entity making the filing
unless such person or entity knows or has reason to believe such information is inaccurate (as provided in Rule 13d-1(k)(1)(ii)). This
Joint Filing Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Remainder of page intentionally left blank;
signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the persons and entities
named below have executed, in counterparts, this Joint Filing Agreement as of the date set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated as of March 18, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">AJP Holding Company, LLC</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/ Jeffrey Wang</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Jeffrey Wang</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Manager</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Jeffrey Wang</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%">By:</TD>
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid">/s/ Jeffrey Wang</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Jeffrey Wang</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Orbic North America, LLC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%">By:</TD>
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid">/s/ Parveen Narula</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Parveen Narula</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Ashima Narula</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/ Ashima Narula</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp; </TD>
    <TD>Ashima Narula</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Parveen Narula</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">/s/ Parveen Narula </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp; </TD>
    <TD>Parveen Narula</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea023943601ex99-2_sonim.htm
<DESCRIPTION>FORM OF VERIFIED COMPLAINT, FILED WITH THE DELAWARE COURT OF CHANCERY ON APRIL 24, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ORBIC NORTH AMERICA, LLC and AJP HOLDING COMPANY, LLC,&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9; Plaintiffs,&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9; v.&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SONIM TECHNOLOGIES, INC., MIKE MULICA, PETER LIU, JAMES CASSANO, and
    JACK STEENSTRA,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9; Defendants.</P></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">)<BR>
)<BR>
)<BR>
)<BR>
)<BR>
)<BR>
)<BR>
)<BR>
)<BR>
)<BR>
)</P></TD>
    <TD STYLE="text-align: left; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: middle">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">C.A. No. 2025-_____-___</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>VERIFIED COMPLAINT&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Plaintiffs Orbic North America,
LLC (&ldquo;Orbic&rdquo;) and AJP Holding Company, LLC (&ldquo;AJP&rdquo; and, together with Orbic, &ldquo;Plaintiffs&rdquo;), by and
through their undersigned counsel, bring this Verified Complaint against Defendants Sonim Technologies, Inc. (&ldquo;Sonim&rdquo; or the
&ldquo;Company&rdquo;), Mike Mulica, James Cassano, Peter Liu, and Jack Steenstra (collectively, the &ldquo;Director Defendants&rdquo;
and, together with the Company, &ldquo;Defendants&rdquo;), and allege upon knowledge as to themselves, and upon information and belief
as to all other matters, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INTRODUCTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. This
action arises from the Director Defendants&rsquo; blatant attempt to weaponize the Company&rsquo;s advance notice bylaw in order to frustrate
legitimate stockholder action. The reason for that attempt is obvious: knowing that the Company&rsquo;s performance has been dismal and
facing a proxy contest by stockholders holding in excess of 30% of the Company&rsquo;s outstanding stock, the Director Defendants seek
to entrench themselves and ensure that Sonim stockholders are prevented from having the opportunity to exercise their franchise to oust
the Director Defendants from office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. Settled
Delaware law provides that advance notice bylaws are intended to &ldquo;permit orderly meetings and election contests and to provide fair
warning to the corporation so that it may have sufficient time to respond to shareholder nominations.&rdquo; But, importantly, the orderly
election processes facilitated by advance notice bylaws &ldquo;inure also&mdash;if not primarily&mdash;to the benefit of shareholders[.]&rdquo;
The Director Defendants have lost sight of this principle and have chosen to impose conditions on Plaintiffs&rsquo; right to nominate
candidates for elections to Sonim&rsquo;s board of directors (the &ldquo;Board&rdquo;) that simply do not exist under any reasonable interpretation
of the Company&rsquo;s bylaws. Instead, the Director Defendants have improperly attempted to twist legitimate information mechanics in
the advance notice bylaws into a tripwire, purely for entrenchment purposes (much like their decision to adopt a poison pill as discussed
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. The
Company&rsquo;s annual meeting (the &ldquo;2025 Annual Meeting&rdquo;) is rapidly approaching and actions taken at that meeting are likely
to signal what the future of the Company holds. Plaintiffs have submitted a director nomination notice (the &ldquo;Nomination Notice&rdquo;)
that put forth five nominees, and identified their skills, experience, and qualifications, to determine the future path for the Company.
As is clear from the Nomination Notice, the professional backgrounds of each of Plaintiffs&rsquo; nominees would benefit the Company at
this pivotal point. The Company though, through the Director Defendants, has improperly rejected Plaintiffs&rsquo; Nomination Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. Although
Plaintiffs&rsquo; Nomination Notice fully complied with the Company&rsquo;s bylaws, Defendants seek to prevent Sonim stockholders from
considering Plaintiffs&rsquo; nominees and deciding for themselves who should serve on the Company&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. The
Director Defendants&rsquo; sole basis for rejecting Plaintiffs&rsquo; Nomination Notice is that the Notice purportedly violated Section
5(b)(1) of the bylaws by not including a conclusory sentence reflecting that the nominees&rsquo; experience, qualifications, attributes,
and skills were the bases for their proposed nomination. No such requirement exists in the bylaws, rather Defendants purport to incorporate
into the bylaws a disclosure requirement in Item 401(e) of Regulation S-K. But Item 401(e) also does not require, under its plain terms,
the conclusory statement that Defendants assert as the basis for the rejection. Rather, Item 401(e) merely requires &ldquo;for each director
or person nominated or chosen to become a director, briefly discuss the specific experience, qualifications, attributes or skills that
led to the conclusion that the person should serve as a director for the registrant at the time that the disclosure is made.&rdquo; The
Nomination Notice plainly included this required information, and Defendants cannot seriously contest otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6. Even
a cursory comparison of the Nomination Notice and the Company&rsquo;s rejection demonstrates this point. For example, the Nomination Notice
provided extensive details as to each nominee&rsquo;s employment history and relevant professional experience, which for some dated back
more than 20 years. In particular, the Nomination Notice explained in detail the positions that each of the proposed nominees had held&mdash;including
executive-level and director roles at leading technology companies&mdash;and relevant work experience of each of the proposed nominees&mdash;including
extensive experience with AI and other cutting-edge technology&mdash;that made the proposed nominees well qualified for a role on the
Board of Sonim, a technology-focused company. While Plaintiffs could have included a conclusory sentence to the effect that &ldquo;we
believe that the expertise and relevant experience of each of our nominees led to our decision to nominate them,&rdquo; neither the bylaws
nor Item 401(e) require this specific nomenclature. Such a statement would add nothing of materiality and there cannot be a reasonable
dispute that the Nomination Notice included material information about nominees&rsquo; &ldquo;specific experience, qualifications, attributes
or skills&rdquo; that led Plaintiffs to seek to nominate them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7. The
Company&rsquo;s rejection of Plaintiffs&rsquo; Nomination Notice violated the Bylaws, and the Director Defendants breached their fiduciary
duties by taking improper efforts to thwart a proxy contest, remove any possibility of a contested election, and entrench themselves in
office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8. Based
on the timing of the Company&rsquo;s annual meeting last year, Plaintiffs believe the 2025 Annual Meeting will be scheduled to be held
in mid-to-late June 2025. Plaintiffs are therefore left with no other option than to seek prompt judicial enforcement of rights as stockholders
to a fair opportunity to nominate qualified candidates for election to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FACTUAL BACKGROUND</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>A.</B></TD><TD><B>The Parties and Relevant Non-Parties</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9. Plaintiff
AJP Holding Company, LLC is a Delaware limited liability company. AJP is a record holder of 1,946,345 shares of common stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10. Plaintiff
Orbic North America, LLC is a New York limited liability company. Orbic is the beneficial owner and proxy holder of the 1,946,345 shares
of common stock of the Company described above. Orbic also holds 1,000 shares of the Company&rsquo;s common stock as a record holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11. Together,
Plaintiffs hold 30.7% of the Company&rsquo;s Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12. Defendant
Sonim Technologies, Inc. is a Delaware corporation headquartered in San Diego, California. Sonim trades on the NASDAQ under the ticker
&ldquo;SONM.&rdquo; Sonim offers mobile technology solutions to individuals in physically demanding workplaces, such as manufacturers,
construction workers, electricians, miners, police, firefighters, and first responders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13. Director
Defendant Mike Mulica has served as a Director of the Company since April 2021 and as the Chairman of Sonim&rsquo;s Board since November
2023. Mulica&rsquo;s current one-year term on the Board expires at the Company&rsquo;s 2025 Annual Meeting and upon the election of his
successor at the 2025 Annual Meeting. Upon information and belief, Mulica will be standing for reelection at the Company&rsquo;s 2025
Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14. Director
Defendant Peter Liu has served as a Director of the Company since July 2022 and as the Company&rsquo;s Chief Executive Officer since April
2022. Prior to becoming the Company&rsquo;s Chief Executive Officer, Liu served as the Company&rsquo;s Executive Vice President for Global
Operations from September 2010 to April 2022. Liu&rsquo;s current one-year term on the Board expires at the Company&rsquo;s 2025 Annual
Meeting and upon the election of his successor at the 2025 Annual Meeting. Upon information and belief, Liu will be standing for reelection
at the Company&rsquo;s 2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15. Director
Defendant James Cassano has served as a Director of the Company since July 2022. Cassano&rsquo;s current one-year term on the Board expires
at the Company&rsquo;s 2025 Annual Meeting and upon the election of his successor at the 2025 Annual Meeting. Upon information and belief,
Cassano will be standing for reelection at the Company&rsquo;s 2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16. Director
Defendant Jack Steenstra has served as a Director of the Company since July 2022. Steenstra&rsquo;s current one-year term on the Board
expires at the Company&rsquo;s 2025 Annual Meeting and upon the election of his successor at the 2025 Annual Meeting. Upon information
and belief, Steenstra will be standing for reelection at the Company&rsquo;s 2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17. Non-party
Jeffrey Wang has served as a Director of the Company since July 2022. Wang is the Manager of AJP. Wang will not stand for re-election
at the 2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18. Non-parties
Douglas B. Benedict, Joseph M. Glynn, Gregory Mark Johnson, Surendra Singh, and Michael Wallace are Plaintiffs&rsquo; nominees to the
Company&rsquo;s Board, as set forth in the Nomination Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>B.</B></TD><TD><B>Sonim Continues to Struggle Under Current Management</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19. As
described in the Company&rsquo;s various SEC filings, Sonim specializes in rugged and durable mobile devices, catering to users who require
extra resilience in their professional and personal lives. Initially focusing on handsets and accessories for the enterprise, first responder,
and government sectors, Sonim has broadened its offerings to include connected devices for wireless internet access, such as mobile hotspots.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20. Over
the last five years, Sonim has experienced a continuous decline in stock price. While Sonim&rsquo;s stock traded for over $125 per share
as recently as February 2021, its stock now trades for only $1.49. This reflects an approximately 99% decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21. Current
management is well aware that Sonim&rsquo;s performance (or lack thereof) has not lived up to the expectations of stockholders. On March
31, 2025, the Company once again announced staggering annual losses, this time of $33.6 million or $7.13 per share. Yet, two days later,
on April 2, 2025, the Board significantly increased the change of control severance payments to which Mr. Liu would be entitled&mdash;an
increase from six months of salary to 150% of 12 months of his salary. This increase in potential severance pay also came after Plaintiffs&rsquo;
Nomination Notice and Indication of Interest (as defined below). Further, on April 12, 2025, the Board increased the change of control
severance payments for Mr. Clay Crolius, the Company&rsquo;s Chief Financial Officer, including by adding a guaranteed pro-rated bonus
of not less than 20% of Mr. Crolius&rsquo;s annual salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>C.</B></TD><TD><B>The Company&rsquo;s Advance Notice Bylaw</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">22. As
set forth in Article V of Sonim&rsquo;s Amended and Restated Certificate of Incorporation, the members of the Company&rsquo;s Board &ldquo;shall
be elected at each annual meeting of stockholders for a term of one year &hellip; [and] until his successor is duly elected and qualified.&rdquo;
Ex. A, Art. V &sect; B.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23. Sonim&rsquo;s
Amended and Restated Bylaws, amended as of June 14, 2024 (the &ldquo;Bylaws&rdquo;), among other things, set forth conditions regarding
stockholder nominations of candidates for election to the Board at the Company&rsquo;s annual meetings (the &ldquo;Advance Notice Bylaw&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">24. In
relevant part, Section 5(b)(1) of the Company&rsquo;s Bylaws provides:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">For nominations for the election to the Board
of Directors to be properly brought before an annual meeting by a stockholder pursuant to clause (iii) of Section 5(a), the stockholder
must deliver written notice to the Secretary at the principal executive officers of the corporation on a timely basis as set forth in
Section 5(b)(3) and must update and supplement such written notice on a timely basis as set forth in Section 5(b)(3) and must update
and supplement such written notice on a timely basis as set forth in Section 5(c). Such stockholder&rsquo;s notice shall set forth: (A)
as to each nominee such stockholder proposes to nominate at the meeting: (1) the name, age, business address and residence address of
such nominee, (2) the principal occupation or employment of such nominee, (3) the class and number of shares of each class of capital
stock of the corporation which are owned of record and beneficially by such nominee, (4) the date or dates on which such shares are acquired
and the investment intent of such acquisition and (5) such other information concerning such nominee as would be required to be disclosed
in a proxy statement soliciting proxies for the election of such nominee as a director in an election contest (even if an election contest
is not involved), or that is otherwise required to be disclosed pursuant to Section 14 of the 1934 Act and the rules and regulations
promulgated thereunder (including such person&rsquo;s written consent to being named as a nominee and to serving as a director if elected);
and (B) the information required by Section 5(b)(4).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">Ex. B, Art. III, &sect; 5(b)(1).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>D.</B></TD><TD STYLE="text-align: justify"><B>Plaintiffs Seek to Nominate Five Directors for Election to the Board at the 2025 Annual Meeting</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">25. Based
on the timing of the Company&rsquo;s annual meeting last year, Plaintiffs believe the Company&rsquo;s 2025 Annual Meeting of stockholders
will be scheduled to be held in mid-to-late June 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">26. Under
the Advance Notice Bylaw, the deadline to submit nominations for the 2025 Annual Meeting was March 22, 2025. <I>See</I> Ex. B, Art. III
&sect; 5.3 (&ldquo;To be timely, the written notice required by Section 5(b)(1) and or 5(b)(2) must be received by the Secretary at the
principal executive offices of the corporation not later than the close of business on the ninetieth (90th) day nor earlier than the close
of business on the one hundred twentieth (120th) day prior to the first anniversary of the preceding year&rsquo;s annual meeting[.]&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27. On
March 20, 2025, Plaintiffs jointly submitted the Nomination Notice to the Company, in compliance with the Bylaws. Ex. C. The Nomination
Notice put forth five director nominees for the Board, to be voted on at Sonim&rsquo;s 2025 Annual Meeting: Benedict, Glynn, Johnson,
Singh, and Wallace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">28. The
Nomination Notice set forth in detail the qualifications and biographies of each of the Nominees, and the rationale for each Nominee&rsquo;s
nomination, and provided all of the information required under Section 5.1 of the Bylaws. Indeed, among other things, the Nomination Notice
provided:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The name and age of each of the Nominees (as required by Section 5.1(b)(1)(A)(1));
</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The business and residence address of each of the Nominees (as required
by Section 5.1(b)(1)(A)(1));</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The principal occupation or employment of Nominee Benedict (as required
by Section 5.1(b)(1)(A)(2)), dating back approximately 20 years ago, which includes significant executive and board-level experience with
technology driven investment firms and a private network service provider that specializes in software business solutions; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The principal occupation or employment of Nominee Glynn (as required by
Section 5.1(b)(1)(A)(2)), dating back approximately 28 years ago, which includes significant board-level experience at a telecommunications
company, an advisory board that helps technology companies connection, collaborate, and contribute to accelerate innovation, and an international
association focused on growing and promoting the use of specific RF bands; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The principal occupation or employment of Nominee Johnson (as required by
Section 5.1(b)(1)(A)(2)), dating back approximately 7 years ago, which includes significant executive experience developing and executing
Orbic&rsquo;s suite of digital financial products, and scaling business revenues through brand and product reimagination and go-to-market
execution; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The principal occupation or employment of Nominee Singh (as required by
Section 5.1(b)(1)(A)(2)), dating back approximately 30 years ago, which includes significant executive experience at Microsoft (25 years)
and at an AI-powered, best-in-class NextGen Cloud Governance and Management platform; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The principal occupation or employment of Nominee Wallace (as required by
Section 5.1(b)(1)(A)(2)), dating back approximately 27 years ago, which includes significant executive experience at Qualcomm Technologies
and board-level experience at LinkNYC (a first-of-its-kind communications network); and </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The fact that none of the Nominees own of record or beneficially own any
capital stock of the Company (as required by Section 5(b)(1)(A)(3) and (4). </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ex. C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29. On
March 21, 2025, Plaintiffs issued a press release in connection with their delivery of the Nomination Notice (the &ldquo;Press Release&rdquo;),
which they attached as an exhibit to their March 21, 2025 Schedule 14A and Schedule 13D amendment. The Press Release explained that Plaintiffs&rsquo;
Nominees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">[W]ere chosen through a comprehensive evaluation
process to identify professionals with complementary backgrounds and experiences related to improving operations, R&amp;D, manufacturing,
supply chain strategy, finance, sales, vendor and customer management and strategy and corporation development in the context of the opportunities
that are available and offered by an association and cross shareholding with Orbic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">Ex. D.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>E.</B></TD><TD STYLE="text-align: justify"><B>Orbic Offers to Acquire Sonim</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">30. On
March 31, 2025, Orbic sent Sonim a non-binding indication of interest to acquire the Company that would result in Sonim&rsquo;s common
stockholders receiving $4.00 per share in cash (the &ldquo;Indication of Interest&rdquo;). Ex. E. Orbic&rsquo;s offer represented an approximately
80% premium over the closing price for Sonim&rsquo;s common stock on the prior trading day, March 28, 2025. Orbic&rsquo;s Indication of
Interest explained that Orbic believed its &ldquo;offer represent[ed] an opportunity for [Sonim] stockholders to achieve extraordinary
value for their shares.&rdquo; <I>Id</I>. at 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">31. The
Indication of Interest explained further that Orbic had &ldquo;no intent to dispose of any material part of Sonim&rsquo;s business&rdquo;
and &ldquo;intended to invest in and support Sonim&rsquo;s overall business and look forward to renewed growth and financial strength
in its business.&rdquo; <I>Id</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">32. Orbic
also indicated that it was ready to &ldquo;negotiate all aspects of&rdquo; the Indication of Interest. <I>Id</I>. at 2. Orbic set a deadline
of 5:00 p.m. EST on April 4, 2025 for the Company to &ldquo;agree on a path to a friendly combination and expedited due diligence,&rdquo;
or Orbic would &ldquo;consider all available options to take its compelling case directly to [Sonim] stockholders.&rdquo; <I>Id</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">33. On
April 4, 2025, a Special Committee of the Board responded to Orbic&rsquo;s Indication of Interest via letter. Ex. F. The Special Committee
&ldquo;agree[d] that a business combination premised on delivering a compelling premium to Sonim&rsquo;s stockholders is critical.&rdquo;
<I>Id</I>. However, the Special Committee questioned whether Orbic could &ldquo;actually consummate [the] proposed offer&rdquo; and requested
conditions &ldquo;to move forward with&rdquo; the parties&rsquo; discussions. <I>Id</I>. Those conditions included (i) no financial contingency,
(ii) proof of funding, and (iii) adjustment to the offer price. <I>Id</I>. The Special Committee requested that Orbic &ldquo;increase
[its] price to an amount in excess of $4.21 per share given that [it] proposed to acquire a controlling interest.&rdquo; <I>Id</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>F.</B></TD><TD STYLE="text-align: justify"><B>Orbic Serves a Section 220 Demand on the Company</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">34. On
the same day as the Indication of Interest, March 31, 2025, Orbic served the Company with a demand for books and records pursuant to 8
<I>Del. C. </I>&sect; 220 (the &ldquo;Section 220 Demand&rdquo;). Orbic&rsquo;s Section 220 Demand sought books and records from the Company
for the purpose of (i) communicating with Sonim stockholders, including regarding the 2025 Annual Meeting, (ii) communicating with Sonim
stockholders concerning potential transactions Orbic may propose to them involving their Sonim stock, and (iii) providing Sonim stockholders
with materials prepared by Sonim. Ex. G at 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">35. By
letter dated April 7, 2025, Sonim responded to the Section 220 Demand. After alleging various deficiencies, Sonim agreed &ldquo;to produce
a targeted set of materials responsive to the Demand Letter[.]&rdquo; Ex. H. As of the date of this submission, Plaintiffs await Sonim&rsquo;s
response to Plaintiffs&rsquo; proposed confidentiality agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>G.</B></TD><TD STYLE="text-align: justify"><B>The Company Improperly Rejects the Nomination Notice </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">36. On
April 7, 2025, Plaintiffs received a letter from Company, signed by Mulica on behalf of the Board, which rejected the Nomination Notice
(the &ldquo;Rejection Letter&rdquo;). Ex. I. The Board identified just a single purported &ldquo;deficiency&rdquo; with respect to the
Nomination Notice, and on that basis alone, prevented Plaintiffs from putting their nominees, who all have the type of professional experience
that Sonim needs most now, for election to the Board up for election at the 2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">37. According
to the Rejection Letter, the Nomination Notice &ldquo;failed to include&rdquo; information required by the Advance Notice Bylaw. Specifically,
the Board claimed in the Rejection Letter that the Nomination Notice omitted a disclosure under Section 5(b)(1) of the Company&rsquo;s
Bylaws, which requires compliance with Item 401(e) of Regulation S-K, as required by Item 7 of Schedule 14A under the Securities Exchange
Act of 1934. <I>Id</I>. at 1. According to the Board, the Nomination Notice did not &ldquo;briefly discuss the specific experience, qualifications,
attributes or skills that led to the conclusion that the person should serve as a director for the [Company].&rdquo; <I>Id</I>. For this
reason and this reason alone, the Company deemed the Nomination Notice as &ldquo;deficient.&rdquo; <I>Id</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">38. On
April 10, 2025, Plaintiffs responded to the Rejection Letter (the &ldquo;April 10 Letter&rdquo;) and explained that the Company&rsquo;s
position with respect to the Nomination Notice was inconsistent with the Advance Notice Bylaw and &ldquo;reflect[ed] a disingenuous attempt
by the Sonim board to entrench itself in violation of its duties.&rdquo; Ex. J at 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">39. As
further explained in the April 10 Letter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">The nomination notice provides extensive
detail as to the experience and qualifications of the nominees, including employment details and relevant experience going back 20 or
more years for most candidates. The notice plainly sets forth the experience and qualifications of our nominees which formed the basis
for the nominations. Nothing more is required.<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify"><I>Id</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">40. Plaintiffs
went on to explain that &ldquo;[t]he nomination notice provided, among other information, (i) the current principal occupation or employment
for each proposed nominee, with a description of their roles and skills; and (ii) a summary of historical employment for each proposed
nominee, with a description of their roles and skills.&rdquo; <I>Id</I>. To be sure, the April 10 Letter provided specific &ldquo;examples
of the information for the proposed nominees included in the nomination notice&rdquo; (explained further below). <I>Id</I>. at 1-2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>H.</B></TD><TD STYLE="text-align: justify"><B>The Board Adopts a Poison Pill </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">41. On
April 21, 2025, the Company announced that the Board adopted a rights plan in response to Orbic&rsquo;s proposal to acquire the Company
(the &ldquo;Poison Pill&rdquo;). The Poison Pill will be activated if any person acquires (or any persons acting as a group acquire) 15.5%
or more (or 20% in the case of certain passive investors) of the Company&rsquo;s outstanding common stock. The Poison Pill does not expire
until November 21, 2026. Much like their rejection of the Nomination Notice, the Director Defendants&rsquo; decision to adopt the Poison
Pill was for no other reason than for entrenchment purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>I.</B></TD><TD STYLE="text-align: justify"><B>The Company&rsquo;s Rejection of the Nomination Notice is both Inequitable and Based on a Fundamental
Misunderstanding of the Advance Notice Bylaw</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">42. Defendants
improperly rejected the Nomination Notice. The Company&rsquo;s position cannot be reconciled with the plain language of the Company&rsquo;s
Bylaws or bedrock Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><B><I>i.</I></B></TD><TD STYLE="text-align: justify"><B><I>Defendants Misinterpret the Requirements of Section 5.1(b)(1) of the Bylaws and Item 401(e)</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">43. At
bottom, Defendants&rsquo; position appears to be that Section 5.1(b)(1) of the Bylaws requires stockholder nominations to include a conclusory
sentence that a nominee was nominated in light of his or her expertise and experience, even if the nomination includes information fully
describing a nominee&rsquo;s relevant experience, qualifications, attributes, or skills. That requirement cannot be found anywhere in
the Advance Notice Bylaw.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">44. The
Advance Notice Bylaw requires only that any stockholder nomination notice set forth, among other things: &ldquo;information concerning
such nominee as would be required to be disclosed in a proxy statement soliciting proxies for the election of such nominee as a director
in an election contest (even if an election contest is not involved), or that is otherwise required to be disclosed pursuant to Section
14 of the 1934 Act and the rules and regulations promulgated thereunder (including such person&rsquo;s written consent to being named
as a nominee and to serving as a director if elected).&rdquo; Ex. B &sect; 5.1(b)(1). By implication, the Advance Notice Bylaw requires
disclosures under Item 401(e), which provides in relevant part:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">In addition, for each director or person
nominated or chosen to become a director, briefly discuss the specific experience, qualifications, attributes or skills that led to the
conclusion that the person should serve as a director for the registrant at the time that the disclosure is made, in light of the registrant&rsquo;s
business and structure.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">17 CFR &sect; 229.401(e).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">45. The
Nomination Notice more than complied with the Advance Notice Bylaw. By way of example, the Nomination Notice included that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Douglas Benedict has served as director and principal of various companies from 2013 to the present, and
has extensive experience in strategic and financial advisory and M&amp;A, including with companies operating in the technology, IT, and
software-as-a-service fields.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Joseph Glynn served as an officer at Qualcomm for almost three decades, as well as serving as a director
for three different technology and telecommunications companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Gregory Johnson has extensive experience as an officer and advisor to multiple companies, including advising
concerning digital financial products and providing business solutions for point-of-sale transactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">Surendra Singh has served in various senior roles with technology-focused companies for decades, including
serving in senior roles at Microsoft Corporation for approximately 25 years. Mr. Singh also has extensive experience in AI and other technology-focused
fields.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">e.</TD><TD STYLE="text-align: justify">Michael Wallace served in various officer roles with Qualcomm for almost 25 years, focused on a variety
of cutting-edge technology fields. Mr. Wallace also served as a director for a communications network company in New York City for several
years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ex. C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">46. Critically,
the Board&rsquo;s Rejection Letter did not identify any material information that Plaintiffs&rsquo; Nomination Notice failed to disclose
to Sonim stockholders to assist them in making a fully informed decision in casting their votes at the 2025 Annual Meeting. And for good
reason: there is none. The specific experience, qualifications, attributes, and skills for each of the proposed nominees identified in
the Nomination Notice were the bases that &ldquo;led [Plaintiffs] to the conclusion&rdquo; that the proposed nominees were well-qualified
to serve as Company directors. Nothing more is required by the Advance Notice Bylaw.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">47. The
fact that Plaintiff&rsquo;s Nomination Notice did not include a single sentence summarizing this conclusion has no bearing on Somin stockholders&rsquo;
ability to exercise an informed judgment as to whether they should vote for or against Plaintiffs&rsquo; nominees. And tellingly, the
Rejection Letter did not question the strength of the Nominees&rsquo; experience, qualifications, attributes, or skills. The Nomination
Notice included all of the material information from which stockholders might conclude&mdash;for themselves&mdash;whether Plaintiffs&rsquo;
nominees possessed the specific experience, qualifications, attributes or skills that might qualify them for Board service. And that is
all that the Advance Notice Bylaw requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><B><I>ii.</I></B></TD><TD STYLE="text-align: justify"><B><I>The Director Defendants Reject the Nomination Notice in a Blatant Attempt to Entrench Themselves</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">48. As
demonstrated above, Plaintiffs complied with the plain terms of the Advance Notice Bylaw. Yet, Defendants chose to reject Plaintiffs&rsquo;
valid Nomination Notice in violation of the Bylaws and the Director Defendants&rsquo; fiduciary duties. If left unremedied, Defendants&rsquo;
wrongful rejection of Plaintiffs&rsquo; Nomination Notice would deny Plaintiffs the opportunity to present their Nominees to the Company&rsquo;s
stockholders in the hopes of restoring Sonim to stability, profitability, and stockholder value creation&mdash;thereby denying Company
stockholders a meaningful choice in the direction of the Company going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">49. The
Company&rsquo;s rejection of the Nomination Notice is a transparent attempt by the Director Defendants to entrench themselves (similar
to the adoption of the Poison Pill) by using the Company&rsquo;s Advance Notice Bylaw requirements as a tripwire to invalidate Plaintiffs&rsquo;
proper Nomination Notice. As the Delaware Supreme Court explain just last year, when a bylaw &ldquo;function[s] as a &lsquo;tripwire&rsquo;
rather than an information-gathering tool&rdquo;&mdash;as here&mdash;it &ldquo;suggest[s] an intention to block the dissidents&rsquo;
effort.&rdquo; <I>Kellner v. AIM ImmunoTech Inc.</I>, 320 A.3d 239, 265 (Del. 2024).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">50. The
Director Defendants&rsquo; attempts to entrench themselves are further highlighted through recent activity taken at the Company, including,
but not limited to, the significant increase of change of control severance payments to which Liu and Crolius would be entitled, as well
as the adoption of the Poison Pill. All the while the Company has recently announced staggering annual losses and experienced a precipitous
stock price drop following an extended period of time, resulting in an approximately 98% decline over the past five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">51. Moreover,
even if Item 401(e) could be interpreted to require a conclusory sentence that each of the Nominees was nominated in light of their expertise
and experience (it does not), such a restriction strikes directly in the face of equity, which seeks to protect stockholder rights established
through decades of settled Delaware law and practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">52. In
other words, a board of directors may not reject a valid nomination notice simply to stave off challenge and entrench themselves, contrary
to the wishes of the stockholders. That is exactly what Defendants have done here (in addition to adopting the Poison Pill).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">53. And
it is especially troubling that Defendants have taken this improper course of action under the circumstances presented in this case. Plaintiffs
are significant stockholders of the Company, holding approximately 30.7% of the Company&rsquo;s common stock. Orbic recently offered to
acquire the Company at an 80% premium. Defendants know that if that deal were to close, the Director Defendants would be removed from
the Board. On top of that, the Director Defendants know that Orbic has served a demand for books and records to further uncover exactly
what is happening at the Company and have expressed an intent to solicit proxies for the 2025 Annual Meeting. While the Director Defendants
should not be risking the Company&rsquo;s future or jeopardizing the remaining equity value of the Company, that is exactly what they
are doing here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COUNT I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Breach of Contract Against the Company)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">54. Plaintiffs
repeat and reallage each of the foregoing paragraphs as if fully set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">55. Under
the Company&rsquo;s Advance Notice Bylaw, the Company is required to acknowledge and accept compliant nominations for elections of directors
when that notice is sent and received by the deadline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">56. As
demonstrated above, Plaintiffs&rsquo; Nomination Notice fully complied with the Advance Notice Bylaw and is valid notice of Plaintiffs&rsquo;
intent to nominate the Nominees for positions as directors of the Company, to be voted upon at the Company&rsquo;s 2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">57. The
Company unjustly and improperly rejected the Nomination Notice, in violation of the plain language of the Advance Notice Bylaw and well-established
Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">58. In
so acting, Defendants are improperly preventing Plaintiffs from proceeding with their Nomination Notice (which was sent in good faith
and without deficiencies). Instead, the Company rejected the Nomination Notice for lack of a conclusory sentence that is not required
by the Bylaws. Ultimately, the Company rejected the Nomination Notice for pretextual reasons to block Plaintiffs from presenting alternative
Board candidates to the stockholders, consistent with their stockholder rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">59. By
rejecting the Nomination Notice, the Company violated the plain and express terms of the Bylaws. This deprives Plaintiffs of their nominating
rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">60. Plaintiffs
have no adequate remedy at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COUNT II</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Breach of Fiduciary Duty Against the Director
Defendants)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">61. Plaintiffs
repeat and reallege each of the foregoing paragraphs as if fully set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">62. The
Director Defendants owe and continue to owe all Sonim stockholders&mdash;including Plaintiffs&mdash;the highest duties of care and loyalty.
The Director Defendants&rsquo; fiduciary duties preclude them from taking any action to favor their own interests ahead of the interests
of the Company or its stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">63. In
breach of their fiduciary duties, the Director Defendants wrongfully rejected the Nomination Notice for the purposes of perpetuating their
Board-level control over the Company. The Director Defendants were seeking to insulate themselves from an election challenge and to block
Plaintiffs from presenting alternative director candidates to stockholders, consistent with Plaintiffs&rsquo; franchise rights as a significant
stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">64. At
bottom, the Director Defendants are unlawfully preventing Plaintiffs as stockholders of the Company from proceeding with their Nomination
Notice and putting their nominees before the Company&rsquo;s stockholders at the 2025 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">65.
Plaintiffs have no adequate remedy at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>PRAYER FOR RELIEF</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREFORE, Plaintiffs respectfully
request that this Court enter an order as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A. Finding
that the Company breached the Bylaws by rejecting the Nomination Notice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B. Finding
that the Nomination Notice complied with the Bylaws and that Plaintiffs&rsquo; nominees must be made available to the Company&rsquo;s
stockholders in the director election at the 2025 Annual Meeting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C. Finding
that the Director Defendants breached their fiduciary duties by rejecting the Nomination Notice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D. Temporarily
and permanently enjoining the Company and its Board from taking any actions to prevent Plaintiffs from exercising their rights under the
Company&rsquo;s Bylaws, including, but not limited to, enjoining the submission of any slate of nominees at the Company&rsquo;s 2025 Annual
Meeting for the election of directors for the Board that does not contain Plaintiffs&rsquo; Nominees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E. Awarding
Plaintiffs their fees, costs, and expenses, including their attorneys&rsquo; fees and costs, incurred in connection with this action;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">F. Granting
such other and further relief as the Court deems proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Matthew W. Murphy (#5938)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">John M. O&rsquo;Toole (#6448)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-size: 10pt">Kevin M. Kidwell (#6988)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">RICHARDS, LAYTON &amp; FINGER, P.A.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">One Rodney Square</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">920 North King Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Wilmington, Delaware&nbsp;&nbsp;19801</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">(302) 651-7700</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">murphy@rlf.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">otoole@rlf.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">kidwell@rlf.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><I>Attorneys for Plaintiffs Orbic North America, LLC and AJP Holding Company, LLC</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Dated: &nbsp;April 24, 2025</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
